NEWS HIGHLIGHTS
Published Studies Related to Farxiga (Dapagliflozin)
Changes in insulin sensitivity and insulin secretion with the sodium glucose
cotransporter 2 inhibitor dapagliflozin. [2014]
CONCLUSIONS: In patients with T2DM and inadequate glycemic control, dapagliflozin
[Effect of dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with glimepiride]. [Article in German] [2013]
to glimepiride in patients with uncontrolled T2DM... CONCLUSIONS: Dapagliflozin added to glimepiride in patients with T2DM
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with glimepiride: a randomized, 24-week, double-blind,
placebo-controlled trial. [2011]
to glimepiride in patients with uncontrolled T2DM... CONCLUSIONS: Dapagliflozin added to glimepiride in patients with T2DM
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate
glycaemic control with metformin: a randomised, double-blind, placebo-controlled
trial. [2010]
metformin... INTERPRETATION: Addition of dapagliflozin to metformin provides a new therapeutic
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of
insulin plus insulin sensitizers: applicability of a novel insulin-independent
treatment. [2009]
CONCLUSIONS: In patients receiving high insulin doses plus insulin sensitizers
Clinical Trials Related to Farxiga (Dapagliflozin)
Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes [Recruiting]
This is a single center, prospective, randomized, double blinded placebo controlled study
conducted I patients with type 1 diabetes. The aim of this study is to examine the additive
effects of GLP-1 agonist and SGLT2 inhibitor in patients with type 1 diabetes in terms of
possible improved glycemic control, reduced glycemic variability, reduced insulin dosages,
additional effects of weight loss and blood pressure reduction.
Drug Interaction Study of Saxagliptin in Combination With Dapagliflozin in Healthy Participants [Completed]
The purpose of this study is to evaluate whether the pharmacokinetics (body
concentrations/metabolism of the drug) of Saxagliptin and Dapagliflozin are affected when
they are administered together
Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC) [Completed]
The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and
Dapagliflozin from a 2. 5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral
administration relative to 2. 5-mg Saxagliptin and 5-mg Dapagliflozin tablets administered
orally together in the fasted state and to demonstrate the BE of Saxagliptin and
Dapagliflozin from a 5-mg Saxagliptin/10-mg Dapagliflozin FDC tablet after oral
administration relative to 5-mg Saxagliptin and 10-mg Dapagliflozin tablets administered
orally together in the fasted state. Demonstrating bioequivalence refers to showing that
the FDC tablet and co-administration of the individual components yield similar blood
levels/concentrations of the drug and are handled by the body similarly.
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus. [Recruiting]
This is an 8-week, single centre, randomized, parallel-group, double-blind,
placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific
insulin sensitivity in patients with Type 2 diabetes mellitus.
Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Ultra Low Doses of Dapagliflozin in Healthy Subjects [Completed]
The purpose of this study is to evaluate the pharmacodynamics (PD), pharmacokinetics (PK),
safety and tolerability following single oral doses of 0. 001 mg to 2. 5 mg dapagliflozin in
healthy subjects.
|
